Moody Aldrich Partners LLC Sells 5,427 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Moody Aldrich Partners LLC reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 276,647 shares of the biopharmaceutical company’s stock after selling 5,427 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Catalyst Pharmaceuticals were worth $5,500,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Arizona State Retirement System grew its position in shares of Catalyst Pharmaceuticals by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock worth $461,000 after purchasing an additional 654 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 681 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Catalyst Pharmaceuticals by 6.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 720 shares in the last quarter. XTX Topco Ltd boosted its position in shares of Catalyst Pharmaceuticals by 7.5% during the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 773 shares in the last quarter. Finally, Strategic Advocates LLC boosted its position in shares of Catalyst Pharmaceuticals by 6.5% during the 2nd quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 864 shares in the last quarter. 79.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Truist Financial increased their price target on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. HC Wainwright increased their price target on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Citigroup raised their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average price target of $29.50.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX traded up $0.04 during mid-day trading on Thursday, reaching $21.38. 64,001 shares of the stock were exchanged, compared to its average volume of 1,200,396. Catalyst Pharmaceuticals, Inc. has a one year low of $11.89 and a one year high of $21.85. The stock has a 50 day simple moving average of $20.31 and a 200-day simple moving average of $17.53. The stock has a market cap of $2.53 billion, a P/E ratio of 39.52, a P/E/G ratio of 3.18 and a beta of 0.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. The business had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. Sell-side analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the transaction, the insider now directly owns 675,124 shares in the company, valued at $13,738,773.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the sale, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 201,058 shares of company stock worth $4,018,188. 11.00% of the stock is currently owned by company insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.